LEFTY Protein Modulation for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively characterize the roles of developmental pathway members in adult tissue homeostasis and disease models, particularly in cancer, where LEFTY proteins are often dysregulated, leading to neoplastic transformation and cancer progression.
Innovation Solution
Administering therapeutic agents that antagonize LEFTY protein expression or activity, such as inhibitory RNAs, antibodies, or small molecules, to inhibit LEFTY's interaction with TGF-β receptors, thereby targeting cancer cells with genomic amplifications or overexpression of LEFTY genes, including breast, liver, and other cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to characterize developmental pathway members in adult tissue, then existing characterization is maintained, but the ability to effectively study cancer and tissue homeostasis is insufficient
Solution Approach 1:
The patent changes the parameter of LEFTY protein expression levels in the system by using genomic amplification to overexpress LEFTY, thereby transforming the biological system state to enable effective characterization of its role in cancer and tissue homeostasis
2Reliability
If LEFTY protein expression is not targeted, then existing treatment approaches are maintained, but cancer progression due to LEFTY dysregulation continues
Solution Approach 1:
The patent applies preliminary anti-action by administering agents that antagonize LEFTY protein expression or activity before cancer can progress, thereby preventing the harmful effects of LEFTY dysregulation in tumor growth and proliferation
Solution Approach 2:
The patent converts the harmful overexpression of LEFTY in cancer into a beneficial diagnostic and therapeutic opportunity by targeting LEFTY-specific agents against tumors that overexpress this protein, thereby transforming the harmful dysregulation into a treatable condition
3Measurement precision
If genomic amplification of LEFTY genes is not detected, then existing diagnostic methods are used, but cancer detection sensitivity is insufficient
Solution Approach 1:
The patent uses detection methods that identify genomic amplification of LEFTY genes, which can be visualized and measured through molecular techniques, thereby enabling precise detection of this specific genetic alteration in cancer samples
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively inhibits LEFTY-mediated signaling pathways, impairing tumor growth and proliferation, and provides a method for detecting cancer through genomic amplification or overexpression of LEFTY genes, offering a therapeutic strategy for various cancer types.
Implementation Method 1
the agent is an inhibitory RNA
Implementation Method 2
the agent is an antibody, an aptamer, an affimer, an inhibitor cysteine-knot, a chimeric protein, or a small molecule
Data Source
AI summary
This disclosure provides data showing that LEFTY inhibits differentiation-promoting pathways such as BMP7/pSMAD5 in breast cancer cell lines, over and above its known role of inhibiting Nodal/pSMAD2. LEFTY competes with BMP7 to bind to its cell surface receptor BMPR2, leading to inhibition of pSMAD5. The LEFTY-BMPR2 interaction is dominant over BMP-BMPR2 in tumorigenic cells, resulting in diminished pSMAD status, whereas in non-tumorigenic cells, there is minimal LEFTY-BMPR2 interaction, increased BMP7-BMPR2 association, and elevated pSMAD. Compositions and methods for inducing or inhibiting expression and/or the activity of LEFTY and BMP proteins are described, which can be used in diagnosis and therapy of cancer and other conditions, and to promote proliferation of stem cells.